Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ketamine for pain, depression, and anxiety in patients with cancer
IRCT20090801002266N24Phase 3Recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine in cancer pain, major depressive disorder (MDD), anxiety disorder and 1 more, sponsored by Isfahan University of Medical Sciences. Started Jun 2026; status: recruiting.
02
Drugs
ketamine
03
Conditions
cancer painmajor depressive disorder (MDD)anxiety disordercancer
Beyond the preview
Go deeper on IRCT20090801002266N24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090801002266N24.